Hikma Pharmaceuticals PLC
Отворен
СекторЗдравеопазване
1,473 -0.87
Преглед
Промяна на цената на акция
24 ч
Минимум
1469
Максимум
1491
Приходи | 165M |
|---|---|
Продажби | 41M 1.7B |
P/E Средно за сектора | 10.771 49.052 |
EPS | 1.07 |
Дивидентна доходност | 5.74 |
Марж на печалбата | 9.698 |
Служители | 9,400 |
EBITDA | 152M 411M |
Препоръки | Купи |
|---|---|
12-месечна прогноза | +23.99% upside |
Дивидентна доходност Средно за сектора | 5.74% 2.36% |
|---|---|
Следващи печалби | 6.08.2026 г. |
Следваща дата на екс-дивидент | 13.08.2026 г. |
Пазарна капитализация | -526M 3.1B |
|---|---|
Предишно отваряне | 1473.87 |
Предишно затваряне | 1473 |
Настроения в новините
By Acuity
43%
57%
118 / 342 Класиране в Healthcare
Hikma Pharmaceuticals PLC Графика
Миналото представяне не гарантира бъдещи резултати.
Относно Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.